TNFRSF9 and neoplasm: For example, the TNFRSF members CD137 (4-1BB) and CD40 showed their potential as immunotherapy targets by stimulating the proliferation and cytotoxic activities of tumor-reactive CD8 T cells directly and indirectly, respectively (Jeong and Park, 2020).